top of page

Your Voice Patient Survey

This is your chance to improve access to osteoporosis medications in BC.

The survey is now live, available only from  October 20 to November 17, 2021.

Go to the Your Voice website to take the survey.

Resources to spread the word

postcard 1.png

Click here to download this postcard to hand to patients

postcard 2.png

Click here to download this poster

bccop poster.png

Click here to download this poster

Other resources:

Letter from Ministry of Health

Subject: [External] Advance notification of Therapeutic Review of Drugs Used for the Primary Prevention of Osteoporosis

This is an advance notification that the Ministry of Health will soon be collecting patient input for our therapeutic review of drugs used for the primary prevention of osteoporosis. The drugs included in our review are as follows:


      Generic names:

  • Oral bisphosphonates: etinodrate, alendronate 10mg and 70mg, alendronate/cholecalciferol, and risedronate;

  • Intravenous (IV) bisphosphonate: zoledronic acid;

  • Selective estrogen receptor modulators: raloxifene;

  • Biologic: denosumab


      Brand names:

  • Oral bisphosphonates: generics;

  • Intravenous (IV) bisphosphonate: Aclasta®, generics;

  • Selective estrogen receptor modulators: Evista® and generics:

  • Biologic: Prolia®


      Drugs used for: the primary prevention of osteoporosis


      Tentative Dates for Input: Wednesday, October 20, 2021 to Wednesday, November 17, 2021 AT MIDNIGHT


You will receive an additional notification once the survey is available for input.


Once the survey is available for input we will also post a PDF of the survey questions so that patients, caregivers, and patient groups can review the questions before filling in the survey, itself.


Once the survey is posted, you can provide input by visiting our website at: .


Thank you,

Pharmaceutical, Laboratory & Blood Services Division - B.C. Ministry of Health

bottom of page